Telomir Pharmaceuticals TELO
NASDAQ TELO
$1.01 -0.01 (-0.98%)
At close: Oct 22, 2026 · 4:00 PM EDT

Telomir Pharmaceuticals (TELO) Amortization of Deferred Charges (2023 - 2024)

Updated

Analysis

Telomir Pharmaceuticals (TELO) Amortization of Deferred Charges (2023 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 Telomir Pharmaceuticals 69.46 Mn 48.89 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 4.34 Mn
Dec 31, 2023 743,750.00
Sep 30, 2023 743,750.00
API Access

Telomir Pharmaceuticals Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=TELO&period=max&api_key=YOUR_API_KEY